# Rash & Diarrhea Prophylaxis With Capivasertib

> **NCT07426822** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Maryam Lustberg** · enrollment: 108 (estimated)

## Conditions studied

- Metastatic HR+/HER2- Breast Cancer

## Interventions

- **DRUG:** Capivasertib
- **DRUG:** Loperamide
- **DRUG:** Fulvestrant
- **DRUG:** Ceterizine

## Key facts

- **NCT ID:** NCT07426822
- **Lead sponsor:** Maryam Lustberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-04
- **Final completion:** 2029-04
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07426822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07426822, "Rash & Diarrhea Prophylaxis With Capivasertib". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07426822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*